Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio USA, Inc. (“YD Bio USA”) entered into a Master Strategic Alliance Agreement (the “Agreement”) with YC Biotech Co., Ltd. (“YC Biotech”) on February 24, 2026. This partnership represents a pivotal advancement in the Company’s mission, establi ...

Core Insights - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [2] Company Overview - Upstream Bio is developing verekitug, a monoclonal antibody that targets the receptor for thymic stromal lymphopoietin (TSLP), which is a key driver of inflammatory responses [2] - Verekitug is currently in separate Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD) [2] - The company aims to address significant unmet medical needs for patients who are underserved by existing treatments [2] Upcoming Events - Rand Sutherland, CEO of Upstream Bio, will participate in investor conferences in March 2026, including: - TD Cowen 46 Annual Health Care Conference on March 4, 2026, at 9:50 a.m. ET [3] - 2026 Leerink Partners Global Healthcare Conference on March 9, 2026, at 1:40 p.m. ET [3] - Live webcasts of these presentations will be available on Upstream Bio's website [1]

分组1 - Axogen, Inc. (AXGN) reported a 4Q25 non-GAAP EPS of $0.07, missing expectations by approximately $0.03 [1] - Revenue for the quarter was $59.9 million, aligning with estimates and reflecting a year-over-year growth of 21.3% [1]

Core Viewpoint - AbCellera Biologics Inc. shares experienced a significant increase following the release of its fourth-quarter 2025 earnings, indicating positive market reaction to the company's performance [2]. Financial Performance - The company reported earnings per share of negative $0.03, outperforming the estimate of negative $0.18 by 83.33% [2]. - Revenue increased by $39.80 million compared to the previous year [2]. - The fourth-quarter results followed a challenging third quarter of 2025, where the company missed earnings per share estimates by $0.02 [3]. Trading Metrics and Technical Analysis - AbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a low of $1.89 [4]. - The stock has a Relative Strength Index (RSI) of 44.92 and has delivered a 14.18% gain over the past 12 months [4]. - The stock closed at $3.22, up 6.27% on Tuesday, and is approximately 28.7% above its 52-week low [4]. Market Sentiment - Benzinga's Edge Stock Rankings indicate that AbCellera Biologics has a negative price trend across all time frames [5].

Summary of Key Points from the Conference Call Industry Overview - The focus is on the Chinese economy and its growth targets for 2026, particularly in the context of the National People's Congress (NPC) and the 15th Five-Year Plan (FYP) [1][3][8]. Core Insights and Arguments - **GDP Growth Target**: The national GDP growth target for 2026 is expected to remain at approximately 5%, despite many provinces lowering their individual targets. This is aimed at maintaining market confidence during the first year of the 15th FYP [3][8]. - **Policy Stance**: The policy approach is characterized as "cushioning over lifting," indicating that significant stimulus measures are not anticipated. The fiscal envelope is expected to remain flat compared to 2025, with an augmented fiscal deficit of 11.6% of GDP and a budget deficit of 4% of GDP [3][5][8]. - **Fiscal Policy**: The initial fiscal package is projected to be largely unchanged from 2025, with a focus on technology localization and infrastructure investment. A modest package of RMB 500-600 billion is anticipated to support consumption and social welfare, with potential mid-year top-ups if growth momentum weakens [5][12][13]. - **Housing Policy**: A pilot program for mortgage subsidies in select cities is expected post-NPC, reflecting a cautious approach to stimulating the housing market [5][12]. - **Sector-Specific Focus**: The 15th FYP is likely to prioritize sectors such as AI, semiconductors, green energy, and biotechnology, shifting from broad-scale expansion to enhancing R&D ecosystems and promoting healthy competition [10][13]. Additional Important Content - **Market Confidence**: Beijing's strategy emphasizes the importance of anchoring market confidence, especially in light of the economic challenges posed by the housing down-cycle and US-China tensions [8][10]. - **Gradual Measures**: The anticipated measures are described as gradual and focused on providing a floor to domestic demand rather than a strong lift, indicating a slow reflation path for the economy [11][12]. - **Long-term Outlook**: The report maintains a forecast of 4.8% real GDP growth and 4.1-4.2% nominal growth for 2026, with infrastructure and exports expected to offset weaknesses in housing and consumption [11][12]. This summary encapsulates the key points from the conference call, highlighting the strategic direction of the Chinese economy and the anticipated fiscal and policy measures for 2026.

Core Viewpoint - Regeneron Pharmaceuticals is positioned for potential long-term growth, driven primarily by its leading product Dupixent, despite facing challenges in other areas of its business [1]. Group 1: Growth Drivers - Dupixent is Regeneron's main growth driver, approved for treating eczema and expanding into new indications like chronic obstructive pulmonary disease (COPD) in 2024 [3][6]. - In the fourth quarter, Regeneron's revenue increased by 3% year over year to $3.9 billion, largely attributed to Dupixent [4]. - Eylea, another key product, has seen a decline in sales due to competition, with combined U.S. sales dropping 28% year over year in the fourth quarter [5]. Group 2: Diversification Efforts - Regeneron is actively working on diversifying its product portfolio beyond Dupixent and Eylea, with a focus on developing new therapies [8]. - The company received approval for a new cancer drug, Lynozyfic, and is exploring candidates in various therapeutic areas, including weight management and rare diseases [9]. - Regeneron's pipeline includes late-stage programs that could help mitigate the impact of patent expirations, particularly for Dupixent, ensuring a robust lineup of products in the coming years [10].

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding its Huntington's disease gene therapy drug, AMT-130, during the class period from September 24, 2025, to October 31, 2025 [1] Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, with AMT-130 as its leading drug candidate aimed at slowing the progression of Huntington's disease [1] - The company faced significant scrutiny due to alleged material misstatements and omissions related to its clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [1] Legal Proceedings - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1] - Investors who purchased shares during the class period are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options, with a deadline to seek lead plaintiff status set for April 13, 2026 [1] Allegations - The complaint alleges that uniQure misrepresented the approval status of its Pivotal Study design by the FDA and downplayed the likelihood of delays in the BLA submission timeline [1] - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from its Phase I/II studies were adequate for BLA submission, leading to a significant drop in share price by over 49% [1]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $154.2 million, consisting of $146 million from Attruby net product revenue, compared to $5.9 million for the same period last year, reflecting a significant increase of $148.3 million [32][33] - For the full year 2025, total revenues reached $502.1 million, up from $221.9 million in 2024, marking an increase of $280.2 million [33] - Operating costs for Q4 2025 were $293.7 million, compared to $231.9 million in the same period last year, driven primarily by a $63.3 million increase in SG&A expenses [34] Business Line Data and Key Metrics Changes - Attruby's net product revenue for Q4 was $146 million, contributing to a total of $362.4 million for the year, with a 35% quarter-over-quarter growth in net product revenue [24][32] - The number of unique patient prescriptions for Attruby reached 7,804, with 1,856 unique prescribers as of February 20, 2026, indicating strong commercial momentum [18][24] Market Data and Key Metrics Changes - Attruby achieved over 25% market share in the ATTR cardiomyopathy market as of December 31, 2025, with continued growth in first-line patient adoption [18][24] - The company anticipates that its pipeline will generate cash in late 2027 and become a cash generation engine by 2028, projecting over $600 million in profit by that year [9][10] Company Strategy and Development Direction - The company is transitioning from a cash-consuming business to one that generates significant cash flows, with a focus on launching three additional products while maintaining steady cash burn [8][9] - The strategy emphasizes establishing a best-in-class commercial engine for genetic disease therapies, leveraging strong clinical data and market positioning [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's fundamentals, despite recent stock volatility, and highlighted the disconnect between intrinsic value and market valuation [11][12] - The company is focused on executing against milestones and believes its intrinsic value has increased due to recent clinical successes [11][12] Other Important Information - The company ended the year with a cash position of $587.5 million and completed the issuance of $632.5 million in convertible notes, providing a strong cash runway for future operations [36] - Management noted that the recent volatility in stock price is primarily due to uncertainty surrounding the Tafamidis IP situation, but they remain confident in Attruby's clinical profile and market positioning [20][22] Q&A Session Summary Question: What are the key drivers behind Attruby's consistent growth despite competitors slowing down? - Management attributed growth to a strong field team, superior clinical data, and a disciplined focus on patient and healthcare professional needs [41][42] Question: When will significant real-world data be available to establish clinical differentiation? - Management indicated that real-world evidence should be available by the end of the year, focusing on early impact and outcomes related to atrial fibrillation [51] Question: How does the company plan to utilize incremental free cash flow in the future? - The company plans to reinvest in R&D and potentially consider share buybacks or dividends if unable to capture the intrinsic value of its assets [54][55] Question: What is the launch readiness for the upcoming products? - The company is preparing for global launches, building on the successful launch of Attruby, and expects to set new standards of care with upcoming products [60][61]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $154.2 million, consisting of $146 million from Attruby net product revenue, compared to $5.9 million for the same period last year, reflecting a significant increase of $148.3 million [31][32] - For the full year 2025, total revenues reached $502.1 million, up from $221.9 million in 2024, marking an increase of $280.2 million [32][34] - Cash burn for the year was $446 million, with a decline in cash burn noted in Q4 relative to Q3, driven by rising revenues and improving operating leverage [6][10] Business Line Data and Key Metrics Changes - Attruby's net product revenue for Q4 was $146 million, contributing to a total of $362.4 million for the year, reflecting broad-based growth across market segments [23][31] - New patient growth for Attruby accelerated to 7,804 new patient starts in Q4, indicating strong commercial momentum [23][24] Market Data and Key Metrics Changes - Attruby achieved over 25% market share in the ATTR cardiomyopathy market as of December 31, 2025, with continued growth in unique patient prescriptions [17][23] - The company anticipates that its pipeline will begin generating cash in late 2027 and become a cash generation engine by 2028, projecting over $600 million in profit by that year [7][8] Company Strategy and Development Direction - The company is transitioning from a cash-consuming business to one that generates significant cash flows, with a focus on launching three additional products in late 2026 or early 2027 [5][11] - The strategy emphasizes establishing a best-in-class commercial engine for genetic disease therapies, with a commitment to R&D efficiency and organic growth rather than M&A [52][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the intrinsic value of the company, despite recent stock price volatility, attributing the disconnect to uncertainty surrounding the Tafamidis IP situation [10][80] - The company is focused on executing against its milestones and believes that its fundamentals have strengthened commercially, clinically, and strategically [10][11] Other Important Information - The company ended the year with a cash position of $587.5 million and completed the issuance of $632.5 million in convertible notes, providing significant cash runway for future operations [35] - Management highlighted the importance of differentiating Attruby's clinical profile and market positioning, asserting that it remains confident in its long-term value despite potential generic competition [80] Q&A Session Summary Question: What are the key drivers behind Attruby's consistent growth despite competitors slowing down? - Management attributed growth to a strong field team, superior clinical data, and a disciplined focus on patient and healthcare professional needs [40][41] Question: When will significant real-world data be available to establish clinical differentiation? - Management indicated that real-world evidence should be available by the end of the calendar year, focusing on early impact and specific patient populations [50] Question: How does the company plan to use incremental free cash flow in the future? - The company intends to reinvest in R&D and potentially consider share buybacks or dividends if unable to capture the intrinsic value of its assets [53] Question: What is the competitive landscape for infigratinib compared to other therapies? - Management believes infigratinib is best-in-class, with a favorable balance of efficacy and safety, setting a new standard in achondroplasia treatment [71] Question: What is the company's perspective on Tafamidis IP and its impact on Attruby? - Management views the Tafamidis IP debate as a sideshow, asserting that Attruby's clinical differentiation will sustain its market position regardless of generic competition [80]

Core Insights - The biotechnology sector is emerging as a leader in early 2026, following a significant rebound after years of underperformance from 2021 to mid-2024 [1][4] - The SPDR S&P Biotech ETF (NASDAQ: IBB) experienced a remarkable 75% surge from its April 2025 lows, outperforming the broader market [2] - The current focus is on whether this catch-up phase will continue or if biotech is entering a sustained leadership phase [3] Fundamental Tailwinds - Global healthcare demand is increasing, leading to strategic investments in biotechnology, particularly in innovation pipelines [5] - Advancements in gene editing and next-generation therapies are accelerating research timelines and expanding medical possibilities [5] - Successful clinical trials and new FDA approvals are providing real valuation support for biotech companies, moving technologies toward commercialization [6] - Public acceptance of biotechnology solutions is growing, which supports demand and long-term adoption [6] M&A and Partnerships - Mergers and acquisitions are a critical theme in 2026, as large pharmaceutical companies face patent expirations and seek to fill revenue gaps through innovative biotech firms [7] - This dynamic creates a supportive environment for biotech valuations, with strategic partnerships and early-stage acquisitions benefiting investors [8] Capital Rotation - There is a noticeable rotation of capital back into higher-beta growth sectors, including biotech, as investors shift focus from mega-cap technology to areas with greater upside potential [9] - Improved risk appetite indicates that biotech is becoming a preferred destination for capital seeking outsized returns [10] Long-term Outlook - Despite inherent risks, the fundamentals of the biotech sector remain strong, with robust drug development pipelines and positive clinical data supporting a favorable long-term outlook [12] - The recent outperformance of biotech reflects improving fundamentals and renewed capital flows, suggesting that leadership could persist into 2026 [13] - The biotechnology sector is increasingly recognized as a space that warrants close attention due to its potential for rapid movement when innovation and capital align [14]